Pfizer Highlights Launches, Late-State Pipeline To Distract From Sluggish Earnings
This article was originally published in The Pink Sheet Daily
Executive Summary
CEO Ian Read admitted tax inversion remains an attractive potential deal-driver for now, though he declined to offer much insight into the company’s near-term M&A strategy.
You may also be interested in...
Pfizer’s Dolsten Explains Why The Big Pharma Can Win The Immuno-Oncology Marathon
Pfizer isn’t considered one of the frontrunners in the immuno-oncology race, but R&D President Mikael Dolsten declares the company, with five agents in the clinic in 2015, will be a force in the therapeutic area.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.
Israeli Company Lands De Novo Clearance For Digital Bone Marrow Application
The US FDA has cleared a novel software application to enhance the analysis of bone marrow smears. Using the AI-powered tool, hematopathologists may be able to better diagnose various blood and marrow diseases.